Review Article
HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions
Table 2
Broadly neutralizing antibodies, target sites, and breadth of neutralization.
| Broadly neutralizing antibodies | Target site | Breadth of neutralization (IC50 < 50 μg/mL) | Study |
| VRC01 | CD4 binding site | 89% of 180 isolates | Huang et al. (2012) [32] | VRC02 | CD4 binding site | 91% of 190 isolates | Wu et al. (2010) [33] | VRC03 | CD4 binding site | 57% of 190 isolates | Wu et al. (2010) [33] | VRC-PGV04 | CD4 binding site | 88% of 162 isolates | Walker et al. (2011) [34] | VRC-PGV04b | CD4 binding site | 71% of 178 isolates | Wu et al. (2011) [35] | CH103 | CD4 binding site | 55% of 196 isolates | Liao et al. (2013) [22] | 2F5 | gp41 | 39% of 92 isolates | Corti et al. (2010) [36] | 2G12 | gp120 | 41% of 90 isolates | Binley et al. (2004) [37] | 4E10 | gp41 | 98% of 162 isolates | Walker et al. (2009) [38] | PG9 | V1-V2 loops | 78% of 180 isolates | Huang et al. (2012) [32] | PGT130 | V3 loop | 52% of 162 isolates | Walker et al. (2011) [34] | PGT151 | gp120-gp41 | 66% of 117 cross-clade isolates | Bonsignori et al. (2014) [39] | PGT152 | gp120-gp41 | 64% of 117 cross-clade isolates | Blattner et al. (2014) [40] |
|
|
Source: http://www.hiv.lanl.gov/.
|